Alpha 2.0
Login Register
» Articles » PMID: 39373532

Improvement in Health-related Quality of Life Questionnaires with Biologic Treatment in Severe Asthma and Comorbid Chronic Rhinosinusitis with or Without Nasal Polyposis: a Real-life Experience

Overview
Journal Ann Med
Publisher Informa Healthcare
Specialty General Medicine
Date 2024 Oct 7
PMID 39373532
Authors
Pierachille Santus
Marina Saad
Anna Casartelli
Rosaria Lorusso
Lisa Milani
Fiammetta Danzo
Paolo Busatto
Dejan Radovanovic
Affiliations
Soon will be listed here.
Abstract

Background: Patients with severe asthma frequently have comorbid chronic rhinosinusitis (CRS) with or without nasal polyps, that can increase the symptom burden and complicate treatment. Real-life clinical data on the impact of biologic treatments on CRS-specific quality-of-life questionnaires are still lacking.

Materials And Methods: In this retrospective real-life study, we collected data from patients with severe asthma with comorbid CRS with/without nasal polyposis at baseline, and after 3, 6 and 12 months of treatment with omalizumab, mepolizumab, benralizumab or dupilumab. In particular, we evaluated improvements in HRQoL as measured by SinoNasal Outcome Test-22 (SNOT-22, 0 - 110), Visual Analog Scale symptom scores (VAS, 0-10), and Asthma Control Test (ACT, 5-25) and the proportion of patients meeting the minimal clinically important difference (MCID).

Results: Disease-specific HRQoL, as measured by SNOT 22 and VAS score improved in all patients at 3, 6, and 12 months of treatment compared with baseline (SNOT-22: 14, IQR: 0-52 vs 10, IQR:0-30 vs 0, IQR:0-15 vs 0, IQR:0-12,  < 0.001, VAS score: 1, IQR: 0-5 vs 0, IQR:0-3 vs 0, IQR:0-2 vs 0, IQR 0-1,  < 0.001). After 3 months of treatment >80% of patients reached the MCID for ACT, while only patients on dupilumab showed to reach a MCID in 100% of cases. The effect size depended upon the symptom burden at baseline.

Conclusions: The study confirms the efficacy of omalizumab, mepolizumab, benralizumab, and dupilumab in a real-life setting, with a rapid improvement in CRS-specific HRQoL and general health status. These data highlight the importance of targeting type 2 inflammation in asthmatic patients with co-existing upper and lower airways disease.The Authors disclose that preliminary data and analysis of the present study have been presented in abstract form during the "X International Workshop on Lung Health - Respiratory Disease and Immune Response", held in Nice on 19-21 January 2023.

References
1.
Bonini M, Di Paolo M, Bagnasco D, Baiardini I, Braido F, Caminati M . Minimal clinically important difference for asthma endpoints: an expert consensus report. Eur Respir Rev. 2020; 29(156). PMC: 9488652. DOI: 10.1183/16000617.0137-2019. View
2.
Frossing L, Silberbrandt A, von Bulow A, Backer V, Porsbjerg C . The Prevalence of Subtypes of Type 2 Inflammation in an Unselected Population of Patients with Severe Asthma. J Allergy Clin Immunol Pract. 2020; 9(3):1267-1275. DOI: 10.1016/j.jaip.2020.09.051. View
3.
Lommatzsch M, Brusselle G, Canonica G, Jackson D, Nair P, Buhl R . Disease-modifying anti-asthmatic drugs. Lancet. 2022; 399(10335):1664-1668. DOI: 10.1016/S0140-6736(22)00331-2. View
4.
Nagase H, Suzukawa M, Oishi K, Matsunaga K . Biologics for severe asthma: The real-world evidence, effectiveness of switching, and prediction factors for the efficacy. Allergol Int. 2022; 72(1):11-23. DOI: 10.1016/j.alit.2022.11.008. View
5.
Bachert C, Han J, Desrosiers M, Hellings P, Amin N, Lee S . Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials. Lancet. 2019; 394(10209):1638-1650. DOI: 10.1016/S0140-6736(19)31881-1. View